- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01345578
Hepatocyte Transplantation for Liver Based Metabolic Disorders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15201
- Children's Hospital of Pittsburgh of UPMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients will have life-threatening liver-based metabolic disorders who are candidates for organ transplantation where hepatocyte transplantation is considered theoretically curative.
- In addition to child subjects less than 18 years of age, for purposes of this protocol, adults up to age 21 years will be enrolled since this is the upper age limit of patients which are seen at Children's Hospital of Pittsburgh.
Exclusion Criteria:
- Patients with liver based metabolic disorders not theoretically treatable with organ transplantation.
Subjects who meet any of the following criteria will be excluded from participation in this protocol:
- Subject has active malignancy.
- Subject has allergy to immunosuppression medications that are required post transplant procedure for the prevention of rejection.
- Subject has sepsis, pneumonia, other active infection or other secondary life-threatening organ dysfunction.
- Significant liver fibrosis determined by biopsy (if clinically indicated). Significant liver fibrosis will be defined by the Ishak Staging, Stage 5: bridges with occasional nodules.
- Subject is pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hepatocyte Transplantation
See Below
|
Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant. If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation.
Other Names:
Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in enzyme physiologic function at 6 months
Time Frame: 6 months post hepatocyte transplant
|
After infusing donor allogeneic hepatocytes through the portal vein following preparative hepatic irradiation, improvement in enzyme physiologic function will be assessed at 6 months.
|
6 months post hepatocyte transplant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ira J Fox, MD, University of Pittsburgh
Publications and helpful links
General Publications
- Horslen SP, Fox IJ. Hepatocyte transplantation. Transplantation. 2004 May 27;77(10):1481-6. doi: 10.1097/01.tp.0000113809.53415.c2.
- Horslen SP, McCowan TC, Goertzen TC, Warkentin PI, Cai HB, Strom SC, Fox IJ. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics. 2003 Jun;111(6 Pt 1):1262-7. doi: 10.1542/peds.111.6.1262.
- Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC, Chowdhury NR, Warkentin PI, Dorko K, Sauter BV, Strom SC. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med. 1998 May 14;338(20):1422-6. doi: 10.1056/NEJM199805143382004. No abstract available.
- Dhawan A, Mitry RR, Hughes RD, Lehec S, Terry C, Bansal S, Arya R, Wade JJ, Verma A, Heaton ND, Rela M, Mieli-Vergani G. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation. 2004 Dec 27;78(12):1812-4. doi: 10.1097/01.tp.0000146386.77076.47.
- Sokal EM, Smets F, Bourgois A, Van Maldergem L, Buts JP, Reding R, Bernard Otte J, Evrard V, Latinne D, Vincent MF, Moser A, Soriano HE. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation. 2003 Aug 27;76(4):735-8. doi: 10.1097/01.TP.0000077420.81365.53.
- Jorns C, Ellis EC, Nowak G, Fischler B, Nemeth A, Strom SC, Ericzon BG. Hepatocyte transplantation for inherited metabolic diseases of the liver. J Intern Med. 2012 Sep;272(3):201-23. doi: 10.1111/j.1365-2796.2012.02574.x. Epub 2012 Aug 20.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO09040497
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Diseases
-
Mondelēz International, Inc.University of SydneyCompletedMetabolic DisorderAustralia
-
Asia UniversityDepartment of Health, Executive Yuan, R.O.C. (Taiwan)Completed
-
Hospital Clinic of BarcelonaNovartisCompletedBone Disease, MetabolicSpain
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Stichting MetakidsCompletedInherited Metabolic DisordersNetherlands
-
San Diego State UniversityRecruitingBone Disease, MetabolicUnited States
-
Nantes University HospitalCentre de Recherche en Nutrition Humaine Ouest (CRNH)CompletedCholesterol; Metabolic Disorder | LipoproteinemiaFrance
-
Istituto Ortopedico RizzoliCompletedOsteopenia | Bone Disease, MetabolicItaly
-
University of AarhusAxellusUnknownMetabolic Bone DisorderDenmark
-
University Hospital, Basel, SwitzerlandCompletedMetabolic DiseaseSwitzerland
Clinical Trials on human hepatocyte transplantation
-
Virginia Commonwealth UniversityWithdrawn
-
BaermedUnknownLiver Cirrhosis | Chronic Liver Disease | Liver InsufficiencyIndonesia
-
International Peace Maternity and Child Health...Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaCompletedInfertility | Primary Ovarian Insufficiency | Premature Ovarian FailureChina
-
Kyoto University, Graduate School of MedicineUnknownLiver Failure, AcuteJapan
-
Midhat H. AbdulredaDiabetes Research Institute Foundation; Bascom Palmer Eye InstituteRecruiting
-
Federal University of São PauloUnknown
-
Xijing HospitalCompleted
-
Emory UniversityJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus, Type 1United States
-
University Hospital, GrenobleAlfediamCompletedType 1 Diabetes MellitusFrance, Switzerland
-
University Hospital, GrenobleTerminatedType 1 Diabetes MellitusFrance, Switzerland